Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Vinayak W Patil1, Rajeev Singhai1, Amit V Patil2, Prakash D Gurav21Department of Biochemistry, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India; 2Department of Surgery, Government Medical College, Miraj, IndiaAbstract: The aim of our study was to analyze triple-negative (TN) breast...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vinayak W Patil, Rajeev Singhai, Amit V Patil, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/16e39405f58945c2bdf9e675a83c38f2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:16e39405f58945c2bdf9e675a83c38f2
record_format	dspace
spelling	oai:doaj.org-article:16e39405f58945c2bdf9e675a83c38f22021-12-02T00:55:02ZTriple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women1179-1314https://doaj.org/article/16e39405f58945c2bdf9e675a83c38f22011-03-01T00:00:00Zhttp://www.dovepress.com/triple-negative-er-pgr-her-2neu-breast-cancer-in-indian-women-a6731https://doaj.org/toc/1179-1314Vinayak W Patil1, Rajeev Singhai1, Amit V Patil2, Prakash D Gurav21Department of Biochemistry, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India; 2Department of Surgery, Government Medical College, Miraj, IndiaAbstract: The aim of our study was to analyze triple-negative (TN) breast cancer, which is defined as being negative for the estrogen receptor (ER), the progesterone receptor (PgR), and the human epidermal growth factor receptor 2 (HER-2/neu) and which represents a subset of breast cancer with different biologic behavior. We investigated the clinicopathological characteristics and prognostic indicators of lymph node-negative TN breast cancer. Medical records were reviewed from patients with node-negative breast cancer who underwent curative surgery at Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, from May 2007 to October 2010. Clinicopathological variables and clinical outcomes were evaluated. Among 683 patients included, 136 had TN breast cancer and 529 had non-TN breast cancer. TN breast cancer correlated with younger age (&lt;35 years, P = 0.003) and a higher histopathologic and nuclear grade (P &lt; 0.001). It also correlated with a molecular profile associated with biological aggressiveness: negative for Bcl-2 expression (P&nbsp;&lt; 0.001), positive for the epidermal growth factor receptor (P = 0.003), and a high level of p53 (P &lt; 0.001) and Ki-67 expression (P &lt; 0.00). The relapse rates during the follow-up period (median 56.8 months) were 14.7% for TN breast cancer and 6.6% for non-TN breast cancer (P = 0.004). Relapse-free survival (RFS) was significantly shorter among patients with TN breast cancer compared with those with non-TN breast cancer: 3.5-year RFS rate 85.5% versus 94.2%, respectively; P = 0.001. On multivariate analysis, young age, close resection margin, and triple negativity were independent predictors of shorter RFS. TN breast cancer had a higher relapse rate and more aggressive clinicopathological characteristics than non-TN in node-negative breast cancer. Thus, TN breast cancer should be integrated into risk factor analysis for node-negative breast cancer.Keywords: TN breast cancer, hormone receptors, ER, PgR, HER-2/neu, Ki-67 Vinayak W PatilRajeev SinghaiAmit V Patilet alDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2011, Iss default, Pp 9-19 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Vinayak W Patil Rajeev Singhai Amit V Patil et al Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
description	Vinayak W Patil1, Rajeev Singhai1, Amit V Patil2, Prakash D Gurav21Department of Biochemistry, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India; 2Department of Surgery, Government Medical College, Miraj, IndiaAbstract: The aim of our study was to analyze triple-negative (TN) breast cancer, which is defined as being negative for the estrogen receptor (ER), the progesterone receptor (PgR), and the human epidermal growth factor receptor 2 (HER-2/neu) and which represents a subset of breast cancer with different biologic behavior. We investigated the clinicopathological characteristics and prognostic indicators of lymph node-negative TN breast cancer. Medical records were reviewed from patients with node-negative breast cancer who underwent curative surgery at Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, from May 2007 to October 2010. Clinicopathological variables and clinical outcomes were evaluated. Among 683 patients included, 136 had TN breast cancer and 529 had non-TN breast cancer. TN breast cancer correlated with younger age (&lt;35 years, P = 0.003) and a higher histopathologic and nuclear grade (P &lt; 0.001). It also correlated with a molecular profile associated with biological aggressiveness: negative for Bcl-2 expression (P&nbsp;&lt; 0.001), positive for the epidermal growth factor receptor (P = 0.003), and a high level of p53 (P &lt; 0.001) and Ki-67 expression (P &lt; 0.00). The relapse rates during the follow-up period (median 56.8 months) were 14.7% for TN breast cancer and 6.6% for non-TN breast cancer (P = 0.004). Relapse-free survival (RFS) was significantly shorter among patients with TN breast cancer compared with those with non-TN breast cancer: 3.5-year RFS rate 85.5% versus 94.2%, respectively; P = 0.001. On multivariate analysis, young age, close resection margin, and triple negativity were independent predictors of shorter RFS. TN breast cancer had a higher relapse rate and more aggressive clinicopathological characteristics than non-TN in node-negative breast cancer. Thus, TN breast cancer should be integrated into risk factor analysis for node-negative breast cancer.Keywords: TN breast cancer, hormone receptors, ER, PgR, HER-2/neu, Ki-67
format	article
author	Vinayak W Patil Rajeev Singhai Amit V Patil et al
author_facet	Vinayak W Patil Rajeev Singhai Amit V Patil et al
author_sort	Vinayak W Patil
title	Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
title_short	Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
title_full	Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
title_fullStr	Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
title_full_unstemmed	Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
title_sort	triple-negative (er, pgr, her-2/neu) breast cancer in indian women
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/16e39405f58945c2bdf9e675a83c38f2
work_keys_str_mv	AT vinayakwpatil triplenegativeerpgrher2neubreastcancerinindianwomen AT rajeevsinghai triplenegativeerpgrher2neubreastcancerinindianwomen AT amitvpatil triplenegativeerpgrher2neubreastcancerinindianwomen AT etal triplenegativeerpgrher2neubreastcancerinindianwomen
_version_	1718403365539414016

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Ejemplares similares